About Antiretroviral Therapy
The antiretroviral therapy (ART) market is primarily related to the treatment of human immunodeficiency virus (HIV) infection. Antiretroviral drugs are usually taken in combination to prevent the growth of the virus, which slows the growth of HIV infection. The major drivers for the ART market include the rising awareness of retroviral infection, aggressive innovation in diagnostic techniques, the introduction of novel drugs through significant investments made in R&D, and high unmet needs in the retrovirus infection treatment domain.
Technavio’s analysts forecast the global antiretroviral therapy market to grow at a CAGR of 2.64% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global antiretroviral therapy market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Antiretroviral Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Gilead
• ViiV Healthcare
• Janssen Pharmaceuticals
• F. Hoffmann-La Roche
Other prominent vendors
• Abbvie
• Boehringer Ingelheim
• Bionor Pharma
• Vertex Pharmaceuticals
• Mylan
Market driver
• Rising awareness of retroviral infection
• For a full, detailed list, view our report
Market challenge
• High cost of antiretroviral drugs
• For a full, detailed list, view our report
Market trend
• Significant pipeline
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: DISEASE OVERVIEW
PART 06: MARKET LANDSCAPE
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY DRUG CLASS
• Multiclass combination products
• NRTIs
• Integrase inhibitors
• NNRTIs
• Others
PART 09: REGIONAL LANDSCAPE
• Regional comparison
• ART market in Americas
• ART market in EMEA
• ART market in APAC
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Significant pipeline
• Advanced formulations
• Funding and treatment initiatives
PART 13: VENDOR LANDSCAPE
• Vendor landscape
PART 14: KEY VENDOR ANALYSIS
• Gilead
• ViiV Healthcare
• Janssen Pharmaceuticals
• F. Hoffmann-La Roche
• Other prominent vendors
PART 15: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Global ART market
Exhibit 02: Global ART market 2016-2021 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline landscape by development phase
Exhibit 05: Key clinical trials
Exhibit 06: Global ART market by drug class 2016
Exhibit 07: Global ART market by drug class 2021
Exhibit 08: Global ART market by multiclass combination products 2016-2021 ($ millions)
Exhibit 09: Global ART market by NRTIs 2016-2021 ($ millions)
Exhibit 10: Global ART market by integrase inhibitors 2016-2021 ($ millions)
Exhibit 11: Global ART market by NNRTIs 2016-2021 ($ millions)
Exhibit 12: Global ART market by others 2016-2021 ($ millions)
Exhibit 13: Global ART market: Regional landscape
Exhibit 14: Regional comparison
Exhibit 15: ART market in Americas 2016-2021 ($ millions)
Exhibit 16: ART market in Americas – Year over year growth 2017-2021
Exhibit 17: ART market in EMEA 2016-2021 ($ millions)
Exhibit 18: ART market in EMEA – Year over year growth 2017-2021
Exhibit 19: ART market in APAC 2016-2021 ($ millions)
Exhibit 20: ART market in APAC – Year over year growth 2017-2021
Exhibit 21: Gilead: Key highlights
Exhibit 22: Gilead: Strength assessment
Exhibit 23: Gilead: Strategy assessment
Exhibit 24: Gilead: Opportunity assessment
Exhibit 25: ViiV Healthcare: Key highlights
Exhibit 26: ViiV Healthcare: Strength assessment
Exhibit 27: ViiV Healthcare: Strategy assessment
Exhibit 28: ViiV Healthcare: Opportunity assessment
Exhibit 29: Janssen Pharmaceuticals: Key highlights
Exhibit 30: Janssen Pharmaceuticals: Strength assessment
Exhibit 31: Janssen Pharmaceuticals: Strategy assessment
Exhibit 32: Janssen Pharmaceuticals: Opportunity assessment
Exhibit 33: F. Hoffmann-La Roche: Key highlights
Exhibit 34: F. Hoffmann-La Roche: Strength assessment
Exhibit 35: F. Hoffmann-La Roche: Strategy assessment
Exhibit 36: F. Hoffmann-La Roche: Opportunity assessment
